Laura Chico Analyst Performance

Managing Director, Equity Research at Wedbush

Laura Chico is a stock analyst at Wedbush focused in the medical sector, covering 38 publicly traded companies. Over the past year, Laura Chico has issued 88 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Laura Chico's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Laura Chico's coverage history, rating activity, and performance tendencies â€” helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 125 Last 8 Years
Buy Recommendations: 74.40% 93 Buy Ratings
Companies Covered: 38 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.8%	1 ratings
Buy	73.6%	92 ratings
Hold	21.6%	27 ratings
Sell	4.0%	5 ratings

Out of 125 total stock ratings issued by Laura Chico at Wedbush, the majority (73.6%) have been Buy recommendations, followed by 21.6% Hold, 4.0% Sell, and 0.8% Strong Buy.

Best & Worst Calls

Best Call
0000.0%
OVID
Mar 2025
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
VTL
Dec 2017
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	89.5% of companies on NASDAQ	34 companies
NYSE	7.9% of companies on NYSE	3 companies
OTCMKTS	2.6% of companies on OTCMKTS	1 company

Laura Chico, an analyst at Wedbush, currently covers 38 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 36 companies	94.7%
	Construction 1 company	2.6%
	Computer and Technology 1 company	2.6%

Laura Chico of Wedbush specializes in stock coverage within the Medical sector, with additional focus on Construction and Computer and Technology companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 29 companies	76.3%
MED - DRUGS 5 companies	13.2%
PHARMACEUTICAL PREPARATIONS 2 companies	5.3%
BLDG - RSDNT/COMR 1 company	2.6%
BUSINESS SOFTWARE SERVICES/BPO 1 company	2.6%

About Laura Chico

Laura brings more than a decade of experience in the biotechnology and drug discovery industry, as well as nine years in Equity Research. During her career, Laura has served as Vice President Equity Research at Raymond James, and as a biotech analyst in the Robert W. Baird Equity Research Healthcare group. Before entering equity research, Laura held scientific roles in both industry and academic settings with focus in central nervous system (“CNS”) diseases such as Alzheimer’s disease. Laura received her B.S. in Bacteriology from the University of Wisconsin-Madison, her M.S. in Computational Biology & Bioinformatics, and her Ph.D. in Molecular Pharmacology, from Northwestern University. She continues to serve as an adjunct assistant professor at Northwestern University’s Feinberg School of Medicine.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
PEPG PepGen	5/13/2026	Lower Price Target	$1.61	$4.00	Outperform
SLDB Solid Biosciences	5/13/2026	Lower Price Target	$7.78	$16.00	Outperform
JBIO Jade Biosciences	5/11/2026	Boost Price Target	$25.81	$34.00	Outperform
CLYM Climb Bio	5/8/2026	Boost Price Target	$11.94	$17.00	Outperform
PRAX Praxis Precision Medicines	5/8/2026	Boost Price Target	$334.73	$166.00	Underperform
DNLI Denali Therapeutics	5/8/2026	Lower Price Target	$19.89	$23.00	Outperform
BCRX BioCryst Pharmaceuticals	5/7/2026	Lower Price Target	$8.66	$21.00	Outperform
DNTH Dianthus Therapeutics	5/6/2026	Boost Price Target	$90.24	$105.00	Outperform
RARE Ultragenyx Pharmaceutical	5/6/2026	Lower Price Target	$25.01	$26.00	Neutral
NBIX Neurocrine Biosciences	5/6/2026	Boost Price Target	$135.06	$176.00	Outperform
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
TVTX Travere Therapeutics	5/5/2026	Boost Price Target	$44.91	$55.00	Outperform
SION Sionna Therapeutics	5/5/2026	Initiated Coverage	$40.45	$53.00	Outperform
SION Sionna Therapeutics	5/4/2026	Upgrade	$40.97		Strong-Buy
BIIB Biogen	4/30/2026	Boost Price Target	$194.38	$196.00	Neutral
OVID Ovid Therapeutics	4/15/2026	Reiterated Rating	$2.96	$7.00	Outperform
TVTX Travere Therapeutics	4/14/2026	Boost Price Target	$41.18	$44.00	Outperform
VRDN Viridian Therapeutics	4/8/2026	Lower Price Target	$13.96	$31.00	Outperform
PHVS Pharvaris	4/7/2026	Boost Price Target	$28.37	$42.00	Outperform
NBIX Neurocrine Biosciences	4/7/2026	Boost Price Target	$132.48	$166.00	Outperform
ANRO Alto Neuroscience	4/2/2026	Lower Price Target	$20.41	$21.00	Neutral
VRDN Viridian Therapeutics	3/31/2026	Lower Price Target	$18.82	$37.00	Outperform
PEPG PepGen	3/31/2026	Lower Price Target	$1.44	$5.00	Outperform
LRMR Larimar Therapeutics	3/20/2026	Boost Price Target	$4.47	$13.00	Outperform
OVID Ovid Therapeutics	3/20/2026	Boost Price Target	$2.30	$7.00	Outperform
EWTX Edgewise Therapeutics	3/17/2026	Reiterated Rating	$29.78	$32.00	Outperform
STOK Stoke Therapeutics	3/17/2026	Boost Price Target	$33.96	$38.00	Outperform
ANRO Alto Neuroscience	3/17/2026	Boost Price Target	$24.27	$22.00	Neutral
XENE Xenon Pharmaceuticals	3/16/2026	Lower Price Target	$55.23	$63.00	Outperform
MAZE Maze Therapeutics	3/16/2026	Boost Price Target	$50.21	$58.00	Outperform
VRDN Viridian Therapeutics	3/11/2026	Reiterated Rating	$29.19	$44.00	Outperform
SLDB Solid Biosciences	3/11/2026	Reiterated Rating	$8.18	$14.00	Outperform
XENE Xenon Pharmaceuticals	3/10/2026	Boost Price Target	$62.76	$64.00	Outperform
DNTH Dianthus Therapeutics	3/10/2026	Boost Price Target	$79.23	$80.00	Outperform
JBIO Jade Biosciences	3/9/2026	Reiterated Rating	$14.05	$24.00	Outperform
CLYM Climb Bio	3/5/2026	Initiated Coverage	$7.28	$12.00	Outperform
LRMR Larimar Therapeutics	3/3/2026	Boost Price Target	$5.36	$12.00	Outperform
LRMR Larimar Therapeutics	2/25/2026	Reiterated Rating	$3.69	$11.00	Outperform
APLS Apellis Pharmaceuticals	2/25/2026	Lower Price Target	$22.13	$18.00	Neutral
GOSS Gossamer Bio	2/24/2026	Reiterated Rating	$0.42	$1.00	Neutral
ARDX Ardelyx	2/23/2026	Reiterated Rating	$5.73	$19.00	Outperform
Millionaire warns: Move your money now (Ad) Larry Benedict, the hedge fund trader who generated $274 million in profits for clients and beat the S&P 500 by 18 times in 2025, says Trump's installation of a new Federal Reserve chair is triggering the most significant shift in U.S. markets in nearly 20 years. Benedict's track record around Fed moves is hard to ignore - 62% from a single position after 2020 rate cuts, 117% in under a month when rate hikes were signaled in 2022, and an 89% gain in 17 days following a Jackson Hole speech. He has already identified the one ticker he believes will be at the center of the coming money flows, and he's sharing it free. Click here to see the ticker Larry Benedict is recommending right now
PRAX Praxis Precision Medicines	2/20/2026	Boost Price Target	$331.61	$130.00	Underperform
RARE Ultragenyx Pharmaceutical	2/17/2026	Reiterated Rating	$20.66	$25.00	Neutral
NBIX Neurocrine Biosciences	2/12/2026	Boost Price Target	$126.00	$151.00	Outperform
DNTH Dianthus Therapeutics	2/11/2026	Boost Price Target	$49.44	$55.00	Outperform
BIIB Biogen	2/9/2026	Boost Price Target	$201.18	$187.00	Neutral
ARDX Ardelyx	1/21/2026	Boost Price Target	$7.76	$19.00	Outperform
STOK Stoke Therapeutics	1/12/2026	Boost Price Target	$32.85	$36.00	Outperform
PRAX Praxis Precision Medicines	1/12/2026	Boost Price Target	$288.45	$95.00	Underperform
DNTH Dianthus Therapeutics	12/22/2025	Reiterated Rating	$42.44	$46.00	Outperform
VERA Vera Therapeutics	12/11/2025	Boost Price Target	$44.34	$33.00	Neutral
DNLI Denali Therapeutics	12/11/2025	Lower Price Target	$17.49	$30.00	Outperform
VRDN Viridian Therapeutics	12/10/2025	Boost Price Target	$31.80	$47.00	Outperform
DNLI Denali Therapeutics	12/5/2025	Boost Price Target	$20.11	$31.00	Outperform
PRAX Praxis Precision Medicines	12/5/2025	Reiterated Rating	$189.97	$83.00	Underperform
ARDX Ardelyx	11/25/2025	Downgrade	$5.50		Hold
PHVS Pharvaris	11/13/2025	Boost Price Target	$26.13	$30.00	Outperform
MAZE Maze Therapeutics	11/7/2025	Boost Price Target	$29.21	$36.00	Outperform
EWTX Edgewise Therapeutics	11/7/2025	Lower Price Target	$17.58	$32.00	Outperform
DNTH Dianthus Therapeutics	11/6/2025	Boost Price Target	$33.73	$46.00	Outperform
PRAX Praxis Precision Medicines	11/6/2025	Boost Price Target	$164.64	$77.00	Underperform
STOK Stoke Therapeutics	11/5/2025	Boost Price Target	$21.20	$32.00	Outperform
ATXS Astria Therapeutics	10/15/2025	Set Price Target	$11.61	$13.00	Neutral
ATXS Astria Therapeutics	10/15/2025	Downgrade	$11.92	$13.00	Neutral
LRMR Larimar Therapeutics	9/30/2025	Lower Price Target	$3.38	$11.00	Outperform
PEPG PepGen	9/25/2025	Boost Price Target	$5.97	$9.00	Outperform
NBIX Neurocrine Biosciences	9/22/2025	Reiterated Rating	$146.62		Outperform
DNTH Dianthus Therapeutics	9/12/2025	Boost Price Target	$37.86	$44.00	Outperform
TRML Tourmaline Bio	9/9/2025	Downgrade	$30.18	$48.00	Neutral
DNTH Dianthus Therapeutics	8/21/2025	Boost Price Target	$23.72	$42.00	Outperform
JBIO Jade Biosciences	8/14/2025	Boost Price Target	$7.03	$18.00	Outperform
SLDB Solid Biosciences	8/13/2025	Lower Price Target	$6.15	$14.00	Outperform
STOK Stoke Therapeutics	8/13/2025	Boost Price Target	$15.66	$22.00	Outperform
XENE Xenon Pharmaceuticals	8/12/2025	Boost Price Target	$36.10	$43.00	Outperform
TVTX Travere Therapeutics	8/7/2025	Boost Price Target	$17.24	$32.00	Outperform
GOSS Gossamer Bio	8/6/2025	Boost Price Target	$1.97	$5.00	Outperform
ARDX Ardelyx	8/5/2025	Reiterated Rating	$5.08	$14.00	Outperform
NBIX Neurocrine Biosciences	7/31/2025	Boost Price Target	$136.76	$141.00	Outperform
RARE Ultragenyx Pharmaceutical	7/14/2025	Lower Price Target	$29.51	$34.00	Neutral
MAZE Maze Therapeutics	7/8/2025	Initiated Coverage	$12.12	$17.00	Outperform
LRMR Larimar Therapeutics	6/24/2025	Lower Price Target	$2.76	$15.00	Outperform
LEN Lennar	6/18/2025	Reiterated Rating	$105.15	$130.00	Neutral
BIIB Biogen	6/12/2025	Reiterated Rating	$132.63	$121.00	Neutral
PHVS Pharvaris	6/5/2025	Reiterated Rating	$16.88	$27.00	Outperform
VIGL Vigil Neuroscience	5/22/2025	Downgrade	$2.31	$8.00	Hold
TVTX Travere Therapeutics	5/16/2025	Reiterated Rating	$17.51	$30.00	Outperform
GOSS Gossamer Bio	5/16/2025	Reiterated Rating	$1.08	$4.00	Outperform
ANRO Alto Neuroscience	5/15/2025	Reiterated Rating	$2.26	$4.00	Neutral
DNLI Denali Therapeutics	5/7/2025	Lower Price Target	$14.02	$30.00	Outperform
VERA Vera Therapeutics	5/7/2025	Lower Price Target	$22.33	$26.00	Neutral
VIGL Vigil Neuroscience	5/5/2025	Reiterated Rating	$2.85	$13.00	Outperform
SpaceX eyes a 1.75 trillion valuation - here's what to know (Ad) Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500. See how to get positioned in SpaceX before the announcement goes public
TVTX Travere Therapeutics	5/2/2025	Reiterated Rating	$20.56	$30.00	Outperform
EWTX Edgewise Therapeutics	4/21/2025	Reiterated Rating	$13.67	$43.00	Outperform
VIGL Vigil Neuroscience	3/14/2025	Lower Price Target	$2.15	$13.00	Outperform
GOSS Gossamer Bio	3/14/2025	Reiterated Rating	$1.35	$4.00	Outperform
OVID Ovid Therapeutics	3/12/2025	Reiterated Rating	$0.49	$3.00	Outperform
ATXS Astria Therapeutics	3/12/2025	Reiterated Rating	$6.47	$28.00	Outperform
DNTH Dianthus Therapeutics	3/12/2025	Reiterated Rating	$22.69	$36.00	Outperform
TRML Tourmaline Bio	3/6/2025	Initiated Coverage	$12.90	$42.00	Outperform
APLS Apellis Pharmaceuticals	3/3/2025	Lower Price Target	$25.15	$29.00	Neutral
SAGE Sage Therapeutics	2/12/2025	Reiterated Rating	$7.24	$6.00	Neutral
NBIX Neurocrine Biosciences	2/7/2025	Lower Price Target	$121.12	$147.00	Outperform
RARE Ultragenyx Pharmaceutical	1/13/2025	Reiterated Rating	$41.84	$48.00	Neutral

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.